Skip to main content
SpringerLink
Log in

Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of this study was to compare the results of somatostatin receptor scintigraphy (SRS) and of radioiodine scintigraphy in patients with metastatic differentiated thyroid carcinoma during L-thyroxine suppression therapy and after withdrawal. Twenty-five patients were studied: 16 patients had papillary cancer and 12 of them had metastatic disease; 9 patients had follicular cancer and 7 of these had known metastases. In 7 patients SRS was performed during thyroxine withdrawal, in 12 during thyroxine therapy within 9 months from radioiodine scintigraphy, in 6 others both during suppression therapy and after withdrawal. SRS was positive in 18 of 25 (72%) patients. It demonstrated lesions in 11 of 13 (85%) patients after thyroxine withdrawal and in 12 of 18 (67%) patients during thyroxine suppression. In 6 patients in whom a direct comparison was made before and after withdrawal, essentially the same information was obtained. Six of 8 (75%) patients with lesions that did not concentrate radioiodine showed uptake of labeled octreotide in these lesions. In 5 of 17 (29%) patients whose tumors concentrated radioiodine, no uptake was found during SRS. Conclusions: 1) in patients with metastatic differentiated thyroid carcinoma, tumor sites can be visualized using SRS; 2) there is no need to withdraw patients from suppression therapy in order to perform SRS; 3) in some patients whose lesions do concentrate labeled octreotide but not radioiodine, the use of somatostatin analogues labeled with 111In or [90Y] can provide new therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hedinger C., Williams E.D., Sabin L.H. The WHO histological classifications of thyroid tumors: a commentary on the second edition. Cancer 1989, 63: 908–911.

    Article  CAS  PubMed  Google Scholar 

  2. Robbins J., Merino M.J., Boice J.D. Thyroid cancer: a lethal endocrine neoplasm. Ann. Intern. Med. 1991, 115: 133–147.

    Article  CAS  PubMed  Google Scholar 

  3. Maxon H.R. III, Smith H.S. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am. 1990, 19: 685–718.

    PubMed  Google Scholar 

  4. Maheshwari Y.K., Hill C.S., Haynie T. I-131 therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 1981, 47: 664–671.

    Article  CAS  PubMed  Google Scholar 

  5. Batge B., Dralle H., Padberg B. Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 reccurent or metastatic tumors. Virchows Arch. 1992, 421: 521–526.

    Article  CAS  Google Scholar 

  6. Mallin W.H., Elgazzar A.H., Maxon H.R. III Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma. Am. J. Otolaryngol. 1994, 15: 417–422.

    Article  CAS  PubMed  Google Scholar 

  7. Brown A.P., Greening W.P., McCready V.R. Radioiodine treatment of metastatic thyroid carcinoma. Br. J. Radiol. 1984, 57: 323–327.

    Article  CAS  PubMed  Google Scholar 

  8. Krenning E.P., Kwekkeboom D.J., Reubi J.C. Peptide receptor scintigraphy in oncology. In: Murray I.P.C., Ell P.J. (Eds.), Nuclear Medicine in clinical diagnosis and treatment, ed. 2. Churchill Livingstone, London, 1998, pp. 859–870.

    Google Scholar 

  9. Tenenbaum F., Lumbroso J., Schlumberger M., Caillou B., Fragu P., Parmentier C. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J. Nucl. Med. 1995, 36: 807–810.

    CAS  PubMed  Google Scholar 

  10. Postema P.T., De Herder W.W., Reubi J.C., Oei H.Y., Kwekkeboom D.J., Bruining H.J., Bonjer J., van Toor H., Hennemann G., Krenning E.P. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996, 57 (Suppl. 1): 36–37.

    Article  PubMed  Google Scholar 

  11. Baudin E., Schlumberger M., Lumbroso J., Travagli J.P., Caillou B., Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J. Clin. Endocrinol. Metab. 1996, 81: 2541–2544.

    CAS  PubMed  Google Scholar 

  12. Reubi J.C., Waser B., Friess H., Krenning E.P., Buchler M., Laissue J. Regulatory peptide receptors in goiters of the human thyroid. J. Nucl. Med. 1997, 38 (Suppl.): 266P.

    Google Scholar 

  13. Garin E., Devillers A., Le Cloirec J., Bernard A.M., Lescouarc’h J., Herry J.Y., Reubi J.C., Bourguet P. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur. J. Nucl. Med. 1998, 25: 687–694.

    Article  CAS  PubMed  Google Scholar 

  14. Krenning E.P., Kooij P.P.M., Pauwels S., Breeman W.A., Postema P.T., de Herder W.W., Valkema R., Kwekkeboom D.J. Somatostatin receptor scintigraphy and radionuclide therapy. Digestion 1996, 57 (Suppl. 1): 57–61.

    Article  CAS  PubMed  Google Scholar 

  15. Krenning E.P., Valkema R., Kooij P.P.M., Breeman W.A.P., Bakker W.H., de Herder W.W., van Eijck C.H.J., Kwekkeboom D.J., de Jong M., Pauwels S. Peptide receptor radionuclide therapy with [Indium-111-DTPA-D-Phe]-octreotide (OC). J. Nucl. Med. 1997, 38: 47P.

  16. Otte A., Jermann E., Behe M., Goetze M., Bucher H.C., Roser H.W., Heppeler A., Mueller-Brand J., Maecke H.R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med. 1997, 24: 792–795.

    CAS  PubMed  Google Scholar 

  17. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., Maecke H.R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998, 351: 417–418.

    Article  CAS  PubMed  Google Scholar 

  18. McCarthy K.E., Woltering E.A., Espenan G.D., Cronin M., Maloney T.J., Anthony L.B. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J. Sci. Am. 1998, 4: 94–102.

    CAS  PubMed  Google Scholar 

  19. Leimer M., Kurtaran A., Smith-Jones P., Raderer M., Havlik E., Angelberger P., Vorbeck F., Niederle B., Herold C., Virgolini I. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J. Nucl. Med. 1998, 39: 2090–2094.

    CAS  PubMed  Google Scholar 

  20. Krenning E.P., Valkema R., Kooij P.P.M., Breeman W.A.P., Bakker W.H., de Herder W.W., van Eijck C.H.J., Kwekkeboom D.J., de Jong M., Pauwels S. Scintigraphy and radionuclide therapy with [Indium-111-labelled-diethyl triamine penta-acetic acid-DPhe1]-octreotide. Ital. J. Gastroenterol. Hepatol. 1999, 31 (Suppl. 2): S219–S223.

    PubMed  Google Scholar 

  21. Krenning E.P., de Jong M., Kooij P.P., Breeman W.A., Bakker W.H., de Herder W.W., van Eijck C.H., Kwekkeboom D.J., Jamar F., Pauwels S., Valkema R. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol. 1999, 10 (Suppl. 2): S23–S29.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Rotterdam, 40 Dr. Molewaterplein, 3015 GD, Rotterdam, The Netherlands

    L. M. Haslinghuis, E. P. Krenning, A. E. M. Reijs &  D. J. Kwekkeboom

  2. Department of Internal Medicine, University Hospital Rotterdam, Rotterdam, The Netherlands

    E. P. Krenning & W. W. de Herder

Authors
  1. L. M. Haslinghuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. P. Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. W. de Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. E. M. Reijs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. J. Kwekkeboom
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haslinghuis, L.M., Krenning, E.P., de Herder, W.W. et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 24, 415–422 (2001). https://doi.org/10.1007/BF03351041

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03351041

Key-words

Search

Navigation